PREDICTORS AND CLINICAL OUTCOMES OF TREATMENT INTENSIFICATION IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN IN A REAL-WORLD SETTING

2018 ◽  
Vol 24 (9) ◽  
pp. 805-814 ◽  
Author(s):  
Lee Kallenbach ◽  
Amy M. Shui ◽  
Wendy Y. Cheng ◽  
Tao Fan ◽  
Wenli Hu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Outcomes ◽  
Real World ◽  
Basal Insulin ◽  
Treatment Intensification ◽  
Real World Setting

scholarly journals Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non‐insulin antidiabetic drugs in a real‐world setting

2019 ◽  
Vol 21 (6) ◽  
pp. 1373-1380 ◽  
Author(s):  
Silvia Canivell ◽  
Manel Mata‐Cases ◽  
Jordi Real ◽  
Josep Franch‐Nadal ◽  
Bogdan Vlacho ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Real World ◽  
Antidiabetic Drugs ◽  
Treatment Intensification ◽  
Real World Setting

scholarly journals First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia

2011 ◽  
Vol 3 (3) ◽  
pp. 208-216 ◽  
Author(s):  
Shih-Tzer TSAI ◽  
Faruque PATHAN ◽  
Linong JI ◽  
Vincent Tok Fai YEUNG ◽  
Manoj CHADHA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Real World Setting

scholarly journals Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States

2018 ◽  
Vol 31 (2) ◽  
pp. 129-137 ◽  
Author(s):  
Anita M. Loughlin ◽  
Qing Qiao ◽  
Anthony P. Nunes ◽  
Stephen M. Ezzy ◽  
Laura Yochum ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
The United States ◽  
Real World Setting

scholarly journals Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study

2018 ◽  
Vol 89 ◽  
pp. 37-42 ◽  
Author(s):  
Diego Bellido ◽  
Pablo Abellán ◽  
José Manuel Ruiz Palomar ◽  
Rogelio Álvarez Sintes ◽  
Andreu Nubiolae ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Real World ◽  
Basal Insulin ◽  
Real World Setting

scholarly journals Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study

2019 ◽  
Vol 7 (1) ◽  
pp. e000884 ◽  
Author(s):  
Reema Mody ◽  
Qing Huang ◽  
Maria Yu ◽  
Hiren Patel ◽  
Xian Zhang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Linear Models ◽  
Statistical Significance ◽  
Economic Outcomes ◽  
Analysis Of Covariance ◽  
Real World Setting ◽  
Baseline Characteristics

AimsTo report 1-year clinical and economic outcomes from the retrospective DISPEL (Dulaglutide vs Basal InSulin in Injection Naïve Patients with Type 2 Diabetes: Effectiveness in ReaL World) Study.Materials and methodsThis observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date). Propensity score matching was used to address treatment selection bias. Change from baseline in hemoglobin A1c (HbA1c) was compared between the matched cohorts using analysis of covariance; diabetes-related costs were analyzed using generalized linear models.ResultsMatched cohorts (903 pairs total; 523 pairs with complete cost data) were balanced in baseline characteristics with mean HbA1c 8.6%, mean age 54 years. At 1 year postindex, dulaglutide patients had significantly greater reduction in HbA1c than basal insulin (−1.12% vs −0.51%, p<0.01), lower medical costs ($3753 vs $7604, p<0.01), higher pharmacy costs ($9809 vs $6175, p<0.01), and similar total costs ($13 562 vs $13 779, p=0.76). Medical and total costs per 1% HbA1c reduction were lower for dulaglutide than basal insulin (medical: $3128 vs $12 673, p<0.01; total: $11 302 vs $22 965, p<0.01), while pharmacy costs per 1% HbA1c reduction were lower without reaching statistical significance ($8174 vs $10 292, p=0.15).ConclusionsIn this real-world study, patients with T2D initiating dulaglutide demonstrated greater HbA1c reduction compared with those initiating basal insulin. Although total diabetes-related costs were similar, the total diabetes-related costs per HbA1c reduction were lower for dulaglutide, highlighting the importance of evaluating effectiveness along with the economic impact of medications.

scholarly journals Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

2018 ◽  
Vol 9 (3) ◽  
pp. 1169-1184 ◽  
Author(s):  
Lawrence Blonde ◽  
Denis Raccah ◽  
Elisheva Lew ◽  
Juliana Meyers ◽  
Elena Nikonova ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Real World ◽  
Basal Insulin ◽  
Treatment Intensification
Sign in / Sign up

Export Citation Format

Share Document